Share

April 2015; 2 (2) ArticleOpen Access

Complete remission of critical neurohistiocytosis by vemurafenib

Philipp Euskirchen, Julien Haroche, Jean-François Emile, Ralph Buchert, Staffan Vandersee, Andreas Meisel
First published February 26, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000078
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1138

Share

Article Figures & Data

Figures

  • Figure 1
    Figure 1 MRI of brainstem manifestation

    MRIs at presentation (A, C) and at 6-month follow-up (B, D) show regression of T2 hyperintensities (A, C) and contrast enhancement (B, D) under vemurafenib treatment.

  • Figure 2
    Figure 2 Assessment of systemic disease activity

    Tc99 scintigraphy (A) and fluorodeoxyglucose PET imaging (B, C) at disease onset 2 years before acute deterioration (A), at current presentation (B), and at 6-month follow-up (C) show regression of glucose uptake in bone lesions under vemurafenib treatment (B, C). PET images were normalized to standardized uptake values. (D) C-reactive protein levels (mg/L) decreased upon targeted therapy. The course of disease is shown from first presentation to the Department of Dermatology to 6-month follow-up.

  1. Philipp Euskirchen, MD,
  2. Julien Haroche, MD, PhD,
  3. Jean-François Emile, MD, PhD,
  4. Ralph Buchert, PhD,
  5. Staffan Vandersee, MD and
  6. Andreas Meisel, MD
  1. From the Departments of Neurology (P.E., A.M.), Nuclear Medicine (R.B.), and Dermatology (S.V.), Charité Universitätsmedizin Berlin, Germany; Service de Médecine Interne (J.H.), Hôpital Pitié-Salpêtrière, Paris, France; and Service de Pathologie (J.-F.E.), Hôpital universitaire Ambroise Paré, Paris, France.
  1. Correspondence to Dr. Euskirchen: philipp.euskirchen{at}charite.de
Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. (1) Berliner Krebsgesellschaft (2) Einstein Foundation Berlin

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. I received honoraria from Glaxo Smith Kline for counseling of patients with histiocytosis on the treatments with targeted therapies.

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. I received honororia for praticipation to scientic Boards on therapy with BRAF inhibitors for Roche and Glaxo Smith Kline

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. I was responsible for a study on BRAF testing funded by Roche and recently published: Emile JF, Tisserand J, Bergougnoux L, Nowak F, Faucher G, Surel S, Lamy A, Lecorre D, Helias-Rodzewicz Z, Hofman P, Sabourin JC, Laurent-Puig P; BRAF EQA Group. Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer. 2013 Oct 11;13:472.

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. 1) PLOS ONE, 2009 2) Journal of Cerebral Blood Flow & Metabolism,2011

Patents:

  1. A patent application on anti-infective and immunomodulatory agents used for preventive antibacterial therapy after stroke has been issued to the European Patent Office (PCT/EP03/02246)

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. 1) commercial, Biomarin 2) commercial, Atheneum Partners GmbH 3) non-profit entity, Deutsche Myasthenie Gesellschaft 4) commercial, NOVARTIS

Speakers' Bureaus:

  1. 1) commercial DIAneering 2) commercial, SIEMENS HealthCare Diagnostics GmbH 3) commercial, SANOFI AVENTIS 4) commercial, GRIFOLS

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. 1) BRAHMS ThermoFischer Scientific 2) SIEMENS HealthCare Diagnostics GmbH

Research Support, Government Entities:

  1. 1) Deutsche Forschungsgemeinschaft, NeuroCure Cluster of Excellence, Exc 257, PI, 6 years 2) Deutsche Forschungsgemeinschaft, Collaborative Research Centres SFB-TRR 43, PI, 8 years 3) Deutsche Forschungsgemeinschaft, Collaborative Research Centres SFB-TRR 84, PI, 6 years 4)Bundesministerium f?r Bildung und Forschung, Center for Stroke Research Berlin, 01 EO 08 01, PI, 6 years 5) European Union?s Seventh Framework Programme, Grant Agreements 201024 and 202213 (European Stroke Network), PI, 5 years

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Abstract

Objective: To describe a patient with life-threatening brainstem neurohistiocytosis who recovered completely upon targeted treatment with the V600E mutation-specific BRAF inhibitor vemurafenib.

Methods: We report clinical, histiologic, genetic, and sequential imaging findings, including fluorodeoxyglucose (FDG)-PET, over a follow-up period of 11 months.

Results: The patient presented with central hyperventilation, skeletal and perirenal Erdheim-Chester disease, and cutaneous Langerhans cell histiocytosis. A BRAF V600E hotspot mutation was detected in all afflicted tissues. Therapy with vemurafenib led to complete and stable clinical remission of CNS lesions and systemic disease that could be demonstrated by brain MRI and whole-body FDG-PET.

Conclusions: Neurologic involvement in Erdheim-Chester disease usually confers a poor prognosis. In this patient, vemurafenib was well-tolerated and highly efficacious for severe brainstem involvement in Erdheim-Chester disease with overlapping Langerhans cell histiocytosis. This case illustrates the heterogeneous phenotypic spectrum of neurohistiocytosis and underscores the importance of genetic testing.

Classification of evidence: This article provides Class IV evidence. This is a single observational study without controls.

GLOSSARY

CIP=
critical illness polyneuropathy;
ECD=
Erdheim-Chester disease;
FDG=
fluorodeoxyglucose;
LCH=
Langerhans cell histiocytosis

Histiocytosis encompasses a group of rare systemic disorders of largely unknown origin, although some forms are likely to arise from neoplastic transformation leading to proliferation of histiocytes in affected tissues. Among them, Erdheim-Chester disease (ECD), which predominantly affects adult patients, is characterized by typical symmetric infiltration of long bones as well as aortal and perirenal involvement. Here we report a case of ECD and cutaneous Langerhans cell histiocytosis (LCH) overlap syndrome with life-threatening CNS involvement due to neurogenic hyperventilation responding dramatically to targeted therapy.

CASE REPORT

A 59-year-old Caucasian woman was admitted to our neurointensive care unit with altered level of consciousness after a suspected syncope. Her medical history included submammary cutaneous lesions, which were diagnosed as LCH 15 months before and treated successfully with thalidomide. In addition, after seeking medical advice for knee pain, a nontraumatic tibial fracture was diagnosed. A bone biopsy was performed and did not demonstrate a malignancy but at the time was considered otherwise nondiagnostic.

At presentation, the patient was somnolent with intact motor function and sensation. She was hyperventilating with pronounced hypocapnia (Pco2 12 mm Hg) and respiratory alkalosis (pH 7.6). Retrospectively, fast breathing had been observed for weeks, as well as dysphagia, fatigue, and lethargy. MRI scans showed T2 hyperintense and partly contrast-enhancing pontine, cerebellar, cerebellar peduncle, and occipital lesions (figure 1, A and C). A chest and abdominal CT showed perirenal and periaortal fibrosis with “hairy kidney” and “coated aorta” appearance, which raised the differential diagnosis of ECD. Supporting evidence was provided by Tc99 scintigraphy, which had been performed 2 years earlier because of the abovementioned nontraumatic tibia fracture and showed symmetric bilateral Tc99 uptake in the long bones of the lower extremities (figure 2A). CSF analysis at the current presentation showed elevated lactate and protein levels but normal cell counts and glucose. The diagnosis of ECD was finally proven by a perirenal biopsy revealing diffuse infiltration of CD1a-negative histiocytes. Reevaluation of skin biopsies, however, confirmed the presence of CD1a-positive histiocytes, whereas the tibia samples showed a histiocytic infiltrate with both CD1a-negative and CD1a-positive phenotypes. Due to recent reports of frequent mutations in the B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene in both Langerhans cell and Erdheim-Chester histiocytosis,1,–,3 sequencing of BRAF exon 15 was performed. A heterozygous V600E point mutation was found in all lesions (perirenal, bone, and skin).

Figure 1
Figure 1 MRI of brainstem manifestation

MRIs at presentation (A, C) and at 6-month follow-up (B, D) show regression of T2 hyperintensities (A, C) and contrast enhancement (B, D) under vemurafenib treatment.

Figure 2
Figure 2 Assessment of systemic disease activity

Tc99 scintigraphy (A) and fluorodeoxyglucose PET imaging (B, C) at disease onset 2 years before acute deterioration (A), at current presentation (B), and at 6-month follow-up (C) show regression of glucose uptake in bone lesions under vemurafenib treatment (B, C). PET images were normalized to standardized uptake values. (D) C-reactive protein levels (mg/L) decreased upon targeted therapy. The course of disease is shown from first presentation to the Department of Dermatology to 6-month follow-up.

Due to respiratory failure from hyperventilation and pneumonia with subsequent sepsis, mechanical ventilation was needed. Neurogenic hyperventilation was treated by morphine application. After a course of 5 × 1 g IV methylprednisolone without clinical benefit, targeted therapy with the oral V600E mutation-specific BRAF inhibitor vemurafenib was started (960 mg twice daily). Rapid improvement in consciousness and hyperventilation was observed within weeks of treatment. Recovery was delayed due to a flaccid tetraparesis caused by critical illness polyneuropathy (CIP).

After 6 months of vemurafenib treatment, the patient had recovered completely from hyperventilation and dysphagia, mental status was normal, and CIP-related motor symptoms had resolved. Brain MRI showed remission of both T2 hyperintensities and contrast enhancement in all infratentorial lesions (figure 1, B and D). Whole-body fluorodeoxyglucose (FDG)-PET (figure 2, B and C) also showed regression of glucose uptake in bone manifestations (maximum standardized uptake values in left humerus lesions at the beginning and after 6 months of treatment: 4.0 vs 1.5). Unfortunately, lower extremities were not imaged in the baseline FDG-PET scan. Cutaneous lesions had regressed under BRAF therapy with residual erythema. C-reactive protein levels stably returned to nearly normal levels (figure 2D). To evaluate whether continuous treatment of stable disease is necessary, vemurafenib has been tapered to a maintenance dosage of 480 mg/day under careful clinical monitoring. No relapse has been observed over the clinical follow-up period of 11 months.

DISCUSSION

ECD is a non-LCH with variable clinical presentation that affects multiple organs. Skeletal involvement with bilateral symmetric histiocytic infiltration of long bones, especially tibiae, as well as perirenal and periaortic infiltrations are most characteristic for the disease. Regarding CNS manifestation, which is a negative prognostic factor,4 hypophysitis, brainstem and cerebellar lesions, and, less commonly, supratentorial lesions have been described.5,–,7 Thus, presentation with diabetes insipidus and ataxia is common.8,–,10 In our case, typical infratentorial lesions were seen, even though presentation with central hyperventilation has not been described before to our knowledge. Neurogenic hyperventilation itself is a rare condition and is usually found in diffuse lesions of the pons and medulla oblongata, although association with cerebellar peduncle lesions has been described.11,12

ECD is differentiated from other forms of histiocytosis by the immunohistochemical phenotype of histiocytic lesions. Typically, lipid-laden CD68+ CD1a− histiocytes surrounded by fibrosis are seen.13 BRAF mutations have recently been described in both LCH and ECD.1,–,3 Here we describe an overlap of both diseases and could verify the key mutation in 3 afflicted organs. Since a brain biopsy was not performed due to the delicate localization of the lesions, it remains unclear whether the CNS infiltration would show CD1a-negative or -positive histiocytes and allow a classification of either ECD or LCH. However, the occasional finding of BRAF mutations in ECD and LCH lesions within the same patient14,–,16 lends further support to the hypothesis that both diseases are of common origin.

For treatment of ECD, use of interferon α, imatinib, cladribine, and recombinant interleukin-1 receptor have been reported, while earlier treatment regimens included steroids and cytotoxic agents. Targeted therapy with vemurafenib has initially been reported in 3 cases,17 and CNS efficacy was recently demonstrated in a patient with suprasellar ECD18 and a case of temporal histiocytic sarcoma.19 Despite severe brainstem involvement, our patient recovered completely upon continuing treatment with vemurafenib. Targeted treatment thus provides an option even when the parenchymal CNS is affected and underscores the importance of BRAF mutation screening in histiocytosis. We continued vemurafenib administration to achieve permanent remission, but prospective studies are needed to investigate maintenance treatment regimens and tolerance.

AUTHOR CONTRIBUTIONS

Dr. Euskirchen: study concept and design, drafting and revising the manuscript. Dr. Haroche: analysis and interpretation of clinical and imaging data. Dr. Emile: acquisition, analysis, and interpretation of histologic data. Dr. Buchert: acquisition, analysis, and interpretation of PET imaging data. Dr. Vandersee: analysis and interpretation of clinical data. Dr. Meisel: study supervision, interpretation of clinical data, drafting and revising the manuscript. All authors approved submission of the manuscript.

STUDY FUNDING

This study was supported by the German Research Foundation (Exc 257, SFB TRR43, to Andreas Meisel).

DISCLOSURE

P. Euskirchen has received research support from Berliner Krebsgesellschaft and Einstein Foundation Berlin. J. Haroche has received honoraria from GlaxoSmithKline. J.-F. Emile has received honoraria from Roche and GlaxoSmithKline and has received research support from Roche. R. Buchert and S. Vandersee report no disclosures. A. Meisel is on the editorial board for PLOS ONE and the Journal of Cerebral Blood Flow & Metabolism; has a patent application for the anti-infective and immunomodulatory agents used for preventive antibacterial therapy after stroke; has consulted for Biomarin, Atheneum Partners GmbH, Sanofi Aventis, and Grifols; has received research support from BRAHMS ThermoFischer Scientific, SIEMENS HealthCare Diagnostics GmbH, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, and European Union's Seventh Framework Programme. Go to Neurology.org for full disclosures.

ACKNOWLEDGMENT

The authors acknowledge Joachim Röwert-Huber, Korinna Jöhrens, and Ioannis Anagnostopoulos for performing histologic analysis and genotyping.

Footnotes

  • Go to Neurology.org/nn for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the authors.

  • Received November 18, 2014.
  • Accepted in final form January 7, 2015.

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

REFERENCES

  1. 1.↵
    1. Badalian-Very G,
    2. Vergilio JA,
    3. Degar BA,
    4. et al
    . Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919–1923.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Haroche J,
    2. Charlotte F,
    3. Arnaud L,
    4. et al
    . High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:2700–2703.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Cangi MG,
    2. Biavasco R,
    3. Cavalli G,
    4. et al
    . BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis Epub 2014 March 26. doi: 10.1136/annrheumdis-2013-204924.
  4. 4.↵
    1. Arnaud L,
    2. Hervier B,
    3. Néel A,
    4. et al
    . CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:2778–2782.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Van der Knaap MS,
    2. Arts WF,
    3. Garbern JY,
    4. et al
    . Cerebellar leukoencephalopathy: most likely histiocytosis-related. Neurology 2008;71:1361–1367.
    OpenUrl
  6. 6.↵
    1. Bianco F,
    2. Iacovelli E,
    3. Tinelli E,
    4. Locuratolo N,
    5. Pauri F,
    6. Fattapposta F
    . Characteristic brain MRI appearance of Erdheim-Chester disease. Neurology 2009;73:2120–2122.
    OpenUrl
  7. 7.↵
    1. Sedrak P,
    2. Ketonen L,
    3. Hou P,
    4. et al
    . Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol 2011;32:2126–2131.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Lefaucheur R,
    2. Maltête D,
    3. Haroche J,
    4. Borden A,
    5. Wallon D,
    6. Bourre B
    . Teaching neuroimages: ataxia and diabetes insipidus. Neurology 2013;81:e19.
    OpenUrl
  9. 9.↵
    1. Liotta EM,
    2. Jhaveri MD,
    3. Fox JC,
    4. Parameswaran V,
    5. Lewis SL
    . Erdheim-Chester disease. Arch Neurol 2012;69:1514–1515.
    OpenUrlPubMed
  10. 10.↵
    1. Cavalli G,
    2. Guglielmi B,
    3. Berti A,
    4. Campochiaro C,
    5. Sabbadini MG,
    6. Dagna L
    . The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013;72:1691–1695.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Ledet D,
    2. Delos Santos NM,
    3. Khan R,
    4. Gajjar A,
    5. Broniscer A
    . Central neurogenic hyperventilation and renal tubular acidosis in children with pontine gliomas. Neurology 2014;82:1099–1100.
    OpenUrl
  12. 12.↵
    1. Tarulli AW,
    2. Lim C,
    3. Bui JD,
    4. Saper CB,
    5. Alexander MP
    . Central neurogenic hyperventilation: a case report and discussion of pathophysiology. Arch Neurol 2005;62:1632–1634.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Haroche J,
    2. Arnaud L,
    3. Amoura Z
    . Erdheim-Chester disease. Curr Opin Rheumatol 2012;24:53–59.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Caoduro C,
    2. Ungureanu CM,
    3. Rudenko B,
    4. et al
    . 18F-fluoride PET/CT aspect of an unusual case of Erdheim-Chester disease with histologic features of Langerhans cell histiocytosis. Clin Nucl Med 2013;38:541–542.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Pineles SL,
    2. Liu GT,
    3. Acebes X,
    4. et al
    . Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J Neuroophthalmol 2011;31:217–223.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Hervier B,
    2. Haroche J,
    3. Arnaud L,
    4. et al
    . Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 2014;124:1119–1126.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Haroche J,
    2. Cohen-Aubart F,
    3. Emile J-F,
    4. et al
    . Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013;121:1495–1500.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Cohen-Aubart F,
    2. Emile JF,
    3. Maksud P,
    4. et al
    . Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology 2014;83:1294–1296.
    OpenUrl
  19. 19.↵
    1. Idbaih A,
    2. Mokhtari K,
    3. Emile JF,
    4. et al
    . Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 2014;83:1478–1480.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement